Carcinoid Tumor (Neuroendocrine Tumor): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Carcinoid tumors, now classified as well-differentiated neuroendocrine tumors (NETs), arise from enterochromaffin cells distributed throughout the body. Primary sites include the gastrointestinal tract (approximately 70%, especially the small intestine, appendix, and rectum), lungs (approximately 25%), and less commonly the pancreas, thymus, and other sites. Annual incidence is approximately 5 per 100,000, and is rising with improved detection through cross-sectional imaging and endoscopy. Most GI NETs are slow-growing WHO grade 1 tumors, but they carry significant potential for liver metastasis — especially small intestinal NETs, which metastasize in approximately 50-70% of cases. The WHO 2019 classification grades NETs based on Ki-67 proliferative index: G1 (<2%), G2 (2-20%), G3 (>20%), and neuroendocrine carcinoma (poorly differentiated, >20%). Carcinoid Tumor (Neuroendocrine Tumor): Causes, Symptoms, Diagnosis and Treatment is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Carcinoid Tumor (Neuroendocrine Tumor): Causes, Symptoms, Diagnosis and Treatment to help patients understand the condition, its causes, symptoms, and available treatment options.

Most NETs are sporadic without identifiable hereditary risk factors. Multiple endocrine neoplasia type 1 (MEN1), caused by germline MEN1 gene mutation, is the most important hereditary predisposition, leading to pancreatic NETs, bronchial carcinoids, gastric type 2 NETs, and pituitary adenomas. Small intestinal NETs show characteristic loss of chromosome 18 and CDKN1B (p27) mutations. Gastric type 1 NETs arise secondary to hypergastrinemia from autoimmune atrophic gastritis (type A). ATRX and DAXX mutations characterize pancreatic NETs associated with alternative lengthening of telomeres. Rectal and appendiceal NETs are rarely associated with germline mutations. Prior radiation therapy and inflammatory bowel disease may contribute to increased GI NET incidence.

Most NETs are clinically silent for years and are discovered incidentally on cross-sectional imaging or endoscopy. Appendiceal and rectal NETs are particularly likely to be incidental findings. Carcinoid syndrome with liver metastases: episodic cutaneous flushing (face, neck, upper chest — most common symptom, occurring in 30-40%), watery secretory diarrhea (20-30 bowel movements per day in severe cases), bronchospasm mimicking asthma, and right-sided cardiac murmur from valvular fibrous plaque (Hedinger syndrome). Functioning pancreatic NETs cause syndrome-specific symptoms: hypoglycemia (insulinoma), peptic ulcers (gastrinoma/Zollinger-Ellison syndrome), necrolytic migratory erythema (glucagonoma), or severe watery diarrhea (VIPoma). Mesenteric fibrosis from small intestinal NETs causes bowel ischemia and abdominal pain.

Biochemical markers: serum chromogranin A (CgA) is the most sensitive general marker; 24-hour urine 5-HIAA (5-hydroxyindoleacetic acid) is specific for serotonin-secreting midgut NETs; specific hormones (fasting insulin and C-peptide, serum gastrin, glucagon, VIP) for functioning pancreatic NETs. 68Ga-DOTATATE PET/CT is the imaging gold standard with sensitivity exceeding 90% for somatostatin receptor-positive grade 1-2 NETs, replacing octreotide scintigraphy. CT or MRI for structural assessment and liver metastasis evaluation. Tissue biopsy for WHO grade (Ki-67), somatostatin receptor expression (SSTR2 IHC), and tumor markers. TNM staging per AJCC 8th edition or ENETS guidelines (different systems for different primary sites). Diagnosis of Carcinoid Tumor (Neuroendocrine Tumor): Causes, Symptoms, Diagnosis and Treatment typically involves a thorough clinical history, physical examination, and targeted investigations. Laboratory tests, imaging studies, or specialist referrals may be required to confirm the diagnosis. Accurate diagnosis is essential for appropriate management and prevents unnecessary treatment.

Surgical resection for localized disease remains the only curative approach, achievable in approximately 30% of patients. Appendiceal NETs less than 2 cm: simple appendectomy is curative. Rectal NETs less than 1 cm: endoscopic resection. Small intestinal NETs: right hemicolectomy plus primary liver resection if feasible. Somatostatin analogues — octreotide LAR (30 mg monthly) and lanreotide (120 mg monthly) — control carcinoid syndrome symptoms and provide antiproliferative benefit for well-differentiated grade 1-2 NETs (PROMID and CLARINET trials). Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is FDA-approved for progressive somatostatin receptor-positive gastroenteropancreatic NETs (NETTER-1 trial: median PFS 28.4 vs 8.5 months). Everolimus (mTOR inhibitor) for progressive pancreatic and non-pancreatic NETs (RADIANT-3, RADIANT-4). Sunitinib for pancreatic NETs. Hepatic artery embolization or TACE for liver-dominant metastatic disease. Telotristat ethyl for refractory carcinoid diarrhea.

Prognosis for neuroendocrine tumors (NETs) varies substantially by grade, primary site, and extent of disease. Localized appendiceal NETs less than 1 cm are cured by appendectomy alone with 5-year OS approaching 100%. Localized rectal NETs less than 1 cm have 5-year OS exceeding 98%. Midgut small intestinal NETs: localized, 5-year OS approximately 90-95%; regional nodal involvement, approximately 80-85%; hepatic metastases present, 5-year OS approximately 65-75% but median OS often exceeds 7-10 years due to indolent growth. Well-differentiated grade 1 NETs with liver metastases treated with somatostatin analogues have median OS exceeding 30-40 months; PRRT extends median PFS from 8.5 to 28.4 months (NETTER-1 trial). Pancreatic NETs: grade 1-2, 5-year OS approximately 60-70% overall; resectable disease approximately 55-65% after surgery. Grade 3 neuroendocrine carcinoma (poorly differentiated): 5-year OS less than 10-15% with platinum-etoposide chemotherapy. Key prognostic factors are WHO grade (Ki-67 index — the most important), somatostatin receptor expression, primary site, resectability, liver tumor burden, hepatic function, and carcinoid heart disease severity. Without treatment, functioning NETs with carcinoid syndrome progress relentlessly; Hedinger syndrome (right-sided valvular fibrosis) worsens prognosis significantly. Long-term surveillance includes chromogranin A and urine 5-HIAA every 3-6 months, 68Ga-DOTATATE PET every 2-3 years or with biochemical progression, and annual echocardiography for carcinoid syndrome patients.

Sporadic NETs have no established modifiable risk factors and therefore no primary prevention strategy. For individuals with known or suspected MEN1 syndrome, genetic counseling and proactive germline testing of first-degree relatives enables identification of mutation carriers before tumor development. MEN1 carriers should undergo structured surveillance per ENETS guidelines: annual biochemical profiling, pancreatic MRI every 1-3 years, and regular upper endoscopy. Individuals with autoimmune atrophic gastritis (type A) should have regular gastroscopic surveillance for gastric type 1 NETs. Early detection of appendiceal NETs through timely appendectomy for appendicitis and incidental discovery at laparoscopy prevents progression to metastatic disease. Routine colonoscopy programs facilitate early detection of rectal NETs smaller than 1 cm that are curable endoscopically.

Seek medical evaluation for: persistent episodic facial or upper body flushing (especially if not associated with alcohol or temperature); chronic secretory diarrhea unexplained by dietary or infectious causes; unexplained wheezing or bronchospasm not responding to standard asthma treatment; an incidental liver mass detected on imaging without a known primary; or symptoms of specific hormonal syndromes such as recurrent hypoglycemia (insulinoma) or refractory peptic ulcers (gastrinoma). Individuals from families with MEN1 syndrome (primary hyperparathyroidism, pituitary adenomas, pancreatic NETs in family members) should undergo formal genetic counseling. New right-sided cardiac murmur in a patient with liver metastases requires echocardiographic assessment for carcinoid heart disease (Hedinger syndrome).